ReviewExperimental & molecular medicine2014
Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines.
Review in Experimental & molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- IFNL3 reduces replication of CIRDC-associated viruses in canine airway epithelial cells.Virus research · 2026Article
- PDGFRα+ fibroblast ablation exacerbates pathologic features in a model of house dust mite-induced allergenic asthma.Disease models & mechanisms · 2025Article
- The intricate interplay among microbiota, mucosal immunity, and viral infection in the respiratory tract.Journal of translational medicine · 2025Review
- Review
- The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines againstClinical and experimental vaccine research · 2024Review
- Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.Vaccine: X · 2023Review
- Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.Frontiers in immunology · 2023Review
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Article
- Development of Nasal Vaccines and the Associated Challenges.Pharmaceutics · 2022Review
- The unfulfilled potential of mucosal immunization.The Journal of allergy and clinical immunology · 2022Review
- Article
- Salmonella Uptake into Gut-Associated Lymphoid Tissues: Implications for Targeted Mucosal Vaccine Design and Delivery.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.Probiotics and antimicrobial proteins · 2021Review
- Advancing Adjuvants forFrontiers in immunology · 2021Review
- Antibody-Mediated Targeting of Antigens to Intestinal Aminopeptidase N Elicits Gut IgA Responses in Pigs.Frontiers in immunology · 2021Article
- Assessment of Immunological Response and Impacts on Fertility Following Intrauterine Vaccination Delivered to Swine in an Artificial Insemination Dose.Frontiers in immunology · 2020Article
- Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.Microorganisms · 2019Review
- Identifying human and murine M cells in vitro.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- Mucosal vaccines and technology.Clinical and experimental immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination is one of the most successful applications of immunology and for a long time has depended on parenteral administration protocols. However, recent studies have pointed to the promise of mucosal vaccination because of its ease, economy and efficiency in inducing an immune response not only systemically, but also in the mucosal compartment where many pathogenic infections are initiated. However, successful mucosal vaccination requires the help of an adjuvant for the efficient delivery of vaccine material into the mucosa and the breaking of the tolerogenic environment, especially in oral mucosal immunization. Given that M cells are the main gateway to take up luminal antigens and initiate antigen-specific immune responses, understanding the role and characteristics of M cells is crucial for the development of successful mucosal vaccines. Especially, particular interest has been focused on the regulation of the tolerogenic mucosal microenvironment and the introduction of the luminal antigen into the lymphoid organ by exploiting the molecules of M cells. Here, we review the characteristics of M cells and the immune regulatory factors in mucosa that can be exploited for mucosal vaccine delivery and mucosal immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.